Genomic classification and risk stratification of bladder cancer
- 248 Downloads
Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.
KeywordsBladder cancer Genetic mutation Classifier Biomarker Risk-classification
Fantini- data collection and management, manuscript writing/editing. Meeks- data collection and management, manuscript writing/editing
JJM is supported by Grant BX003692 and the John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Compliance with ethical standards
All research involving human subjects should refer back to primary studies.
Conflicts of interest
JJM is a consultant for AstraZeneca and Ferring and receives research funding from Epizyme, NextCure, Abbvie and Tesaro.
- 1.Howlader NNA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, National Cancer Institute. Bethesda, MDGoogle Scholar
- 7.Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477 (discussion 475–467) CrossRefGoogle Scholar
- 18.Riaz N, Havel JJ, Makarov V et al (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171(934–949):e915Google Scholar
- 22.mutSignatures: Decipher Mutational Signatures from Somatic Mutational CatalogsGoogle Scholar
- 23.Fantini D, Seiler R, Meeks JJ (2018) Molecular footprints of muscle-invasive bladder cancer in smoking and non-smoking patients. Urol OncolGoogle Scholar
- 24.Glaser AP, Fantini D, Rimar KJ et al (2017) APOBEC-Mediated Mutagenesis In Urothelial Carcinoma Is Associated With Improved Survival, Mutations In DNA Damage Response Genes, And Immune Response. bioRxivGoogle Scholar
- 35.Sjodahl G, Eriksson P, Lovgren K et al (2018) Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. Modern PatholGoogle Scholar